新闻简报：WEX 在韩国招募了患者，作为跨国2B期临床试验的一部分，评估Halneuron®在化疗引起的神经性疼痛疗中的疗效和安全性。
Vancouver, BC (March 21, 2023) – WEX Pharmaceuticals Inc. (“WEX” or the “Company”), a biotechnology company developing Halneuron® (Tetrodotoxin or TTX) for pain, announced that the first patient in Korea has been enrolled in its multinational Phase 2B clinical trial evaluating the efficacy and safety of Tetrodotoxin in the treatment of Chemotherapy-Induced Neuropathic Pain (the “Clinical Trial”).
新闻简报：WEX 宣布管理层变更
Vancouver, BC (February 8, 2023) ‐ WEX Pharmaceuticals Inc. (“WEX” or the “Company”), a biotechnology company developing Halneuron® (Tetrodotoxin or TTX) for pain, is pleased to announce the following executive appointments, effective immediately. Mr. Walter Korz will assume the role of Chief Executive Officer (CEO) of the Company, and Mr. Abner Yong will assume the role of Chief Financial Officer.